# PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

> **NCT05175742** · PHASE2 · COMPLETED · sponsor: **Providence Therapeutics Holdings Inc.** · enrollment: 565 (actual)

## Conditions studied

- Covid19 Vaccine

## Interventions

- **BIOLOGICAL:** PTX-COVID19-B
- **BIOLOGICAL:** Pfizer-BioNTech COVID-19 vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05175742
- **Lead sponsor:** Providence Therapeutics Holdings Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-17
- **Primary completion:** 2023-03-29
- **Final completion:** 2023-03-29
- **Target enrollment:** 565 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05175742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05175742, "PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05175742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*